Eledon Pharmaceuticals: Promising Kidney Transplant Program and Strong Financial Position Support Buy Rating

Tip Ranks
2025.11.16 20:55
portai
I'm PortAI, I can summarize articles.

LifeSci Capital's Rami Katkhuda maintains a Buy rating on Eledon Pharmaceuticals, citing promising kidney transplant program developments and a strong financial position. The Phase II BESTOW study showed tegoprubart's differentiated safety profile, despite not achieving eGFR superiority. Eledon has $93.4 million in cash and plans a Phase III study in 2026. Noble Financial also reiterated a Buy rating with a $10.00 price target.

In a report released today, Rami Katkhuda from LifeSci Capital maintained a Buy rating on Eledon Pharmaceuticals, with a price target of $4.00.

Meet Your ETF AI Analyst

  • Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
  • Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.

Rami Katkhuda’s rating is based on Eledon Pharmaceuticals’ promising developments in their kidney transplantation program. The company has reported positive topline data from the Phase II BESTOW study, which evaluated the safety and efficacy of tegoprubart compared to tacrolimus in kidney transplant patients. While the study did not achieve statistical superiority in eGFR levels, tegoprubart demonstrated a differentiated safety profile with fewer opportunistic infections and lower rates of metabolic, neurologic, and cardiovascular toxicities compared to the current standard of care.
Despite the lack of eGFR superiority, the noninferior efficacy and meaningful safety benefits of tegoprubart provide a viable commercial opportunity in kidney transplantation. Eledon’s financial position is also strong, with $93.4 million in cash and recent financing of $57.5 million to support the continued development of tegoprubart. The company plans to advance to a Phase III study in 2026, which further supports the Buy rating given the potential for long-term growth and success in this therapeutic area.

In another report released on November 10, Noble Financial also reiterated a Buy rating on the stock with a $10.00 price target.

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.